reason report
qualiti guidanc in-lin trough
bottom line manag widen ebitda guidanc rang
indic trough year new combin
compani viatri reset outlook consist forecast
expect ebitda mostli flat versu growth
start multipl headwind china upjohn
busi remain uncertainti around newco reset
thu expect stock pressur tomorrow
make littl chang ebitda estim
lower price target reflect slightli lower peer multipl
reiter market perform rate
beat low qualiti driven lower spend lower
tax rate total mylan revenu miss consensu
howev non-gaap ep beat consensu ep
beat driven lower vs consensu sg
spend well lower tax rate
guidanc larg line prior outlook adjust
fx impact manag guid total revenu
mid-point lower financi outlook given
juli due unfavor foreign exchang impact major
geograph segment compani expect north america grow
low singl digit europ grow mid-to-high singl digit rest
world mid-singl digit manag guid adjust ebitda
mid-point lower prior outlook due
averag dilut share outstand revenu
guidanc includ revenu new product launch
ogivri biosimilar herceptin insulin glargin two major
one manag point
manag expect trough year combin
compani line forecast merger upjohn remain
track close mid-year expect new manag team
issu guidanc deal close anticip
trough year term revenu ebitda
consid impact china volume-bas procur vbp
program lyrica celebrex loss exclus japan
outlook much differ model
expect combin compani reach revenu ebitda trough
essenti flat continu expect
growth newco come
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
viatri manag team final appoint
cfo last board member announc
appoint sanjeev narula current cfo upjohn cfo
viatri mr narula spent past year work
cfo frank damelio upjohn presid michael goettler
extens experi emerg market well broad knowledg
gener brand pharmaceut busi two compani
also appoint current board member cornwel serv
last board director choos complet
viatri board director includ current board
appointe
modest model updat pt base latest guidanc
lower north america revenu forecast beyond
result revenu forecast mid-point
guidanc ebitda forecast littl chang
slightli lower valuat framework consid
share viatri lower price target
reflect lower multipl peer
place market perform rate share base see steep declin
upjohn busi come year due loss exclus loe lyrica us
japan faster expect impact china volume-bas procur vbp
sale ebitda estim lower consensu compani outlook
believ investor expect point see stand-alone busi
grow low singl digit best key major product declin clear
sustain growth driver pipelin see combin busi start
grow believ fulli understood see busi
deterior faster realiz cost synergi time see revenu
use ev/ebitda multipl pro forma ebitda
combin compani viatri deriv price target per share base mylan
ownership viatri
exist main franchis may face competit price pressur new launch
may under-perform expect due sub-optimal execut combin compani may
grow faster expect new product launch revenu synergi profit
could improv aggress cost save
brand
type event
event trial detail
date known
up/down
expect
svb leerink llc equiti research compani file
adjust revenu
adjust sg revenu
weight averag number share
non- adjust
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
wixela/ advair assum get approv
letairi approv end march
ulor settlement june tent approv
gilenya compound patent expir aug ped pend approv temporari injunct
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
januvia franchis assum compound patent tent approv
treanda assum launch end bendeka ode dec
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
equiti valu newco
upsid current market cap
